NASDAQ:INMB

INmune Bio News Headlines

$13.62
+2.85 (+26.46 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.52
Now: $13.62
$14.00
50-Day Range
$10.77
MA: $13.68
$18.83
52-Week Range
$3.92
Now: $13.62
$29.99
Volume572,067 shs
Average Volume291,076 shs
Market Capitalization$203.39 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01

Headlines

INmune Bio (NASDAQ INMB) News Headlines Today

SourceHeadline
INmune Bio, Inc. (NASDAQ:INMB) Expected to Post Earnings of -$0.23 Per ShareINmune Bio, Inc. (NASDAQ:INMB) Expected to Post Earnings of -$0.23 Per Share
americanbankingnews.com - April 8 at 4:22 PM
INmune Bio, Inc. (NASDAQ:INMB) Short Interest UpdateINmune Bio, Inc. (NASDAQ:INMB) Short Interest Update
americanbankingnews.com - April 2 at 5:12 AM
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical MeetingsINmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
finance.yahoo.com - March 22 at 9:48 AM
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
finance.yahoo.com - March 8 at 9:50 AM
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business UpdateINmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
finance.yahoo.com - March 4 at 7:55 PM
INmune Bio, Inc. to Host Earnings CallINmune Bio, Inc. to Host Earnings Call
finance.yahoo.com - March 4 at 2:55 PM
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
finance.yahoo.com - February 25 at 12:57 PM
We Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business GrowthWe Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business Growth
finance.yahoo.com - January 25 at 8:51 AM
Why INmune Bio Stock Soared Then Sank TodayWhy INmune Bio Stock Soared Then Sank Today
finance.yahoo.com - January 23 at 10:47 PM
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b TrialINmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
finance.yahoo.com - January 21 at 8:08 AM
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ETINmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
finance.yahoo.com - January 13 at 9:31 AM
Do Hedge Funds Love Inmune Bio Inc. (INMB)?Do Hedge Funds Love Inmune Bio Inc. (INMB)?
finance.yahoo.com - November 27 at 3:48 PM
Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of DirectorsBexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors
finance.yahoo.com - November 17 at 1:57 PM
INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call TranscriptINmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 9:33 AM
INmune Bio EPS misses by $0.19INmune Bio EPS misses by $0.19
seekingalpha.com - November 5 at 8:58 PM
INmune Bio, Inc. Announces Third Quarter Results and Provides Business UpdateINmune Bio, Inc. Announces Third Quarter Results and Provides Business Update
finance.yahoo.com - November 5 at 8:58 PM
INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
finance.yahoo.com - October 29 at 1:24 PM
Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)?Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)?
finance.yahoo.com - October 26 at 8:54 AM
INmune Bio to present preliminary phase I data on Alzheimer’s drug discoveryINmune Bio to present preliminary phase I data on Alzheimer’s drug discovery
seekingalpha.com - October 5 at 2:14 PM
INmune Bio to present interim data from early-stage Alzheimer’s studyINmune Bio to present interim data from early-stage Alzheimer’s study
seekingalpha.com - October 5 at 2:14 PM
INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug DiscoveryINmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
markets.businessinsider.com - October 5 at 9:14 AM
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
finance.yahoo.com - September 23 at 9:09 AM
INmune Bio secures $2.9M funding to advance a mid-stage depression study with lead drugINmune Bio secures $2.9M funding to advance a mid-stage depression study with lead drug
seekingalpha.com - September 16 at 9:26 AM
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant DepressionINmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
finance.yahoo.com - September 16 at 9:26 AM
INmune Bio, Inc. to Participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020.INmune Bio, Inc. to Participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020.
finance.yahoo.com - September 14 at 8:14 AM
INmune Bio receives patent for covering INKmune therapyINmune Bio receives patent for covering INKmune therapy
seekingalpha.com - September 3 at 12:45 PM
INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune™ TherapyINmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune™ Therapy
finance.yahoo.com - September 3 at 12:45 PM
INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 PatientsINmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients
finance.yahoo.com - September 1 at 1:34 PM
INmune Bio Inc.INmune Bio Inc.
barrons.com - August 20 at 10:00 AM
INmune Bio nabs European patent for XPro1595INmune Bio nabs European patent for XPro1595
seekingalpha.com - August 13 at 12:25 PM
European Patent Granted Covering INmune Bio’s XPro1595European Patent Granted Covering INmune Bio’s XPro1595
finance.yahoo.com - August 13 at 12:25 PM
INmune Bio EPS beats by $0.03INmune Bio EPS beats by $0.03
seekingalpha.com - August 5 at 7:22 PM
INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business UpdateINmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update
finance.yahoo.com - August 5 at 7:22 PM
INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020
finance.yahoo.com - August 3 at 7:09 AM
INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial ResultsINmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results
finance.yahoo.com - July 31 at 7:08 AM
INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine StormINmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
finance.yahoo.com - July 27 at 7:48 AM
Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment OptionCorrection: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
finance.yahoo.com - July 20 at 6:24 PM
INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment OptionINmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
finance.yahoo.com - July 20 at 1:23 PM
INmune Bio prices IPO at $10INmune Bio prices IPO at $10
seekingalpha.com - July 16 at 1:08 PM
INmune Bio: Stronger Support From Alzheimers Drug XPro1595INmune Bio: Stronger Support From Alzheimer's Drug XPro1595
seekingalpha.com - July 16 at 1:08 PM
INmune Bio, Inc. Prices Public Offering of Common StockINmune Bio, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - July 16 at 1:08 PM
Relative Strength Alert: Will the Inmune Bio Inc (NAQ:INMB) share price keep rising?Relative Strength Alert: Will the Inmune Bio Inc (NAQ:INMB) share price keep rising?
uk.finance.yahoo.com - July 16 at 8:07 AM
INmune Bio launches stock offeringINmune Bio launches stock offering
seekingalpha.com - July 15 at 7:30 PM
INmune Bio, Inc. Announces Proposed Public Offering of Common StockINmune Bio, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 15 at 7:30 PM
Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's NewsTiny Biotech Skyrockets To A Record High On Promising Alzheimer's News
finance.yahoo.com - July 14 at 5:49 PM
Stock Alert: INmune Bio Hits New 52-week High On Promising Trial ResultsStock Alert: INmune Bio Hits New 52-week High On Promising Trial Results
markets.businessinsider.com - July 14 at 12:47 PM
INmune Surges Higher On Interim Alzheimers DataINmune Surges Higher On Interim Alzheimer's Data
www.msn.com - July 14 at 12:47 PM
Pre-market Movers In Healthcare Sector: INMB, ECOR, CYAD, VXRT...Pre-market Movers In Healthcare Sector: INMB, ECOR, CYAD, VXRT...
www.finanznachrichten.de - July 14 at 7:41 AM
INmune lead drug shows encouraging action in early-stage Alzheimers studyINmune lead drug shows encouraging action in early-stage Alzheimer's study
seekingalpha.com - July 13 at 9:41 PM
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s DiseaseINmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
finance.yahoo.com - July 13 at 9:41 PM
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.